CD8+ T-Cell Depletion & Validation Kit (YTS 169.4) (ICH8265A-5F)

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

The CD8+ T-Cell Depletion & Validation Kit (ICH8265) is a mouse-directed research toolkit that bundles the reagents needed both to deplete CD8+ T cells in vivo and to confirm that depletion by flow cytometry. The two rat immunoglobulin isotypes listed (Rat IgG2b and Rat IgG1 Kappa) are consistent with a depleting anti-mouse CD8 antibody paired with a non-competing detection/validation antibody, so that depletion efficiency can be tracked without the therapeutic clone masking the readout. It is supplied for research use only, at in-vivo-appropriate purity and low endotoxin, and in quantities intended for repeated dosing across a study. Kits of this type are widely used in tumour immunology, infection, autoimmunity and transplantation models to test whether an observed phenotype depends on cytotoxic CD8+ T cells. Because it is a kit rather than a defined single clone, investigators should confirm the exact component clones, formats and validated applications with ichor.bio before designing a study. Content here is guidance for ichor.bio to review and adjust to the finalised kit composition. CD8+ T cells are the principal cytotoxic effector lymphocytes of the adaptive immune system. They recognise peptide antigens presented on MHC class I via their T-cell receptor together with the CD8 co-receptor, and on activation kill infected or transformed target cells through perforin/granzyme release and Fas-mediated pathways, while secreting IFN-gamma and TNF. In mouse models they are central to anti-tumour immunity, control of intracellular pathogens, and graft rejection. Selective depletion of CD8+ T cells is the standard loss-of-function approach for establishing whether a given protective or pathogenic response is CD8-dependent. Anti-CD8 antibodies typically target CD8a (Lyt-2); reliable interpretation depends on confirming the extent and duration of depletion, which is why a paired validation reagent that binds a distinct, non-competing epitope is included so residual CD8+ cells can be quantified during and after treatment.